Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

Open access
Moran, Gordon W, Gordon, Morris, Sinopoulou, Vassiliki, Radford, Shellie J, Darie, Ana-Maria, Vuyyuru, Sudheer Kumar, Alrubaiy, Laith, Arebi, Naila, Blackwell, Jonathan, Butler, Thomas D, Chew, Thean, Colwill, Michael, Cooney, Rachel, De Marco, Gabriele, Din, Said, Din, Shahida, Feakins, Roger, Gasparetto, Marco, Gordon, Hannah, Hansen, Richard, Kok, Klaartje B, Lamb, Christopher A, Limdi, Jimmy, Liu, Eleanor, Loughrey, Maurice B, McGonagle, Dennis, Patel, Kamal, Pavlidis, Polychronis, Selinger, Christian, Shale, Matthew, Smith, Philip J, Subramanian, Sreedhar, Taylor, Stuart A, Tun, Gloria Shwe Zin, Verma, Ajay Mark, Wong, Newton A C S·2025·Gut

Abstract

In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revised in 2019. These updated guidelines aim to complement the IBD standards and promote the use of the national primary care diagnostic pathway for lower gastrointestinal symptoms to enhance diagnostic accuracy and timeliness. Formulated through a systematic and transparent process, this document reflects a consensus of best practices based on current evidence. The guideline, while developed primarily for the UK, is structured to support IBD management internationally. It is endorsed by the BSG executive board and CSSC without external commercial funding, with involvement primarily supported through professional roles in public institutions and the National Health Service (NHS). Methodological revisions since the prior guidelines have enhanced rigor in technical review and development, with methodology details published independently following peer review. In developing the recommendations, 89 clinical experts and stakeholders participated in an online survey, identifying primary outcomes, such as clinical and endoscopic remission, as well as adverse event metrics, all stratified by clinically relevant effect sizes. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2024-334395

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 20 references

Research works printed but not linked: 748

  1. Darie, 2023, BSG 2024 IBD guidelines protocol (standard operating procedures), BMJ Open Gastroenterol, 10, 10.1136/bmjgast-2022-001067 · DOI
  2. Gordon M , Shaban N , Sinopoulou V , et al . n.d. Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions. Inflamm Bowel Dis. doi:10.1093/ibd/izaf085 · DOI
  3. 10.1136/bmj.324.7341.827 · DOI · Paper page
  4. 10.1053/j.gastro.2020.12.031 · DOI · Paper page
  5. Rajagopalan, 2020, Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge, JGH Open, 4, 267, 10.1002/jgh3.12268 · DOI
  6. 10.1002/ibd.21493 · DOI · Paper page
  7. Spekhorst, 2014, Performance of the Montreal classification for inflammatory bowel diseases, World J Gastroenterol, 20, 15374, 10.3748/wjg.v20.i41.15374 · DOI
  8. 10.1038/ajg.2009.177 · DOI · Paper page
  9. 10.1007/s10350-005-0160-3 · DOI
  10. 10.1159/000104731 · DOI
  11. 10.1136/gut.2003.038505 · DOI · Paper page
  12. 10.1155/2005/269076 · DOI · Paper page
  13. 10.1016/0016-5085(94)90054-x · DOI · Paper page
  14. 10.1016/j.cgh.2017.06.016 · DOI · Paper page
  15. Langholz, 1996, Changes in extent of ulcerative colitis: a study on the course and prognostic factors, Scand J Gastroenterol, 31, 260, 10.3109/00365529609004876 · DOI · Paper page
  16. 10.1097/01.MIB.0000225339.91484.fc · DOI · Paper page
  17. 10.1056/NEJM198712243172603 · DOI · Paper page
  18. 10.1002/ibd.20520 · DOI · Paper page
  19. Kafil, 2018, Cannabis for the treatment of ulcerative colitis, Cochrane Database Syst Rev, 11
  20. 10.1136/gutjnl-2011-300486 · DOI · Paper page
  21. 10.1053/j.gastro.2013.07.024 · DOI · Paper page
  22. 10.1093/ecco-jcc/jjv111 · DOI · Paper page
  23. Lee, 2019, Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease, Clin Endosc, 52, 129, 10.5946/ce.2018.042 · DOI
  24. 10.1016/j.cgh.2015.06.001 · DOI · Paper page
  25. 10.1097/01.MIB.0000164024.10848.0a · DOI
  26. Bojic, 2017, Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data, J Crohns Colitis, 11, S576
  27. James E , Morris G , Gaurav BN , et al . British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. Gut 2025. doi:10.1136/gutjnl-2025-335023 · DOI
  28. Pabla, 2020, Assessing Severity of Disease in Patients with Ulcerative Colitis, Gastroenterol Clin North Am, 49, 671, 10.1016/j.gtc.2020.08.003 · DOI
  29. 10.1136/gutjnl-2016-312307 · DOI
  30. Stevens, 2021, Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis, Clin Gastroenterol Hepatol, 19, 2333, 10.1016/j.cgh.2020.08.019 · DOI
  31. Dulai, 2023, Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis, Clin Gastroenterol Hepatol, 21, 456, 10.1016/j.cgh.2022.07.027 · doi:10.1016/j.cgh.2022.07.027
  32. Walsh, 2019, Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis, J Crohns Colitis, 13, 424, 10.1093/ecco-jcc/jjy184 · DOI
  33. Cannatelli, 2021, Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients, Inflamm Bowel Dis, 27, 647, 10.1093/ibd/izaa163 · DOI
  34. Kawashima, 2023, Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission, Inflamm Bowel Dis, 29, 359, 10.1093/ibd/izac095 · doi:10.1093/ibd/izac095
  35. 10.1038/ajg.2015.120 · DOI · Paper page
  36. 10.1093/ecco-jcc/jjad108 · DOI · Paper page
  37. Allocca, 2023, Early Intestinal Ultrasound Predicts Long-Term Endoscopic Response to Biologics in Ulcerative Colitis, J Crohns Colitis, 17, 1579, 10.1093/ecco-jcc/jjad071 · DOI
  38. Allocca, 2021, Point-of-Care Ultrasound in Inflammatory Bowel Disease, J Crohns Colitis, 15, 143, 10.1093/ecco-jcc/jjaa151 · DOI
  39. Bots, 2021, Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index, J Crohns Colitis, 15, 1264, 10.1093/ecco-jcc/jjab002 · DOI
  40. Goodsall, 2024, Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study, Inflamm Bowel Dis, 30, 190, 10.1093/ibd/izad043 · DOI
  41. 10.1136/flgastro-2021-102065 · DOI
  42. 10.1136/gut.2005.082909 · DOI · Paper page
  43. 10.1097/00054725-200002000-00002 · DOI · Paper page
  44. Harvey, 1980, A SIMPLE INDEX OF CROHN’S-DISEASE ACTIVITY, The Lancet, 315, 514, 10.1016/S0140-6736(80)92767-1 · DOI · Paper page
  45. Best, 1976, Development of a Crohn’s Disease Activity Index, Gastroenterology, 70, 439, 10.1016/S0016-5085(76)80163-1 · DOI · Paper page
  46. Summers, 1979, National Cooperative Crohn’s Disease Study: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8 · DOI · Paper page
  47. 10.1053/gast.2002.31072 · DOI · Paper page
  48. 10.1056/NEJM199905063401804 · DOI · Paper page
  49. 10.1097/01.MIB.0000215091.77492.2a · DOI · Paper page
  50. 10.1515/CCLM.2005.073 · DOI
  51. E Penna, 2020, Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease, BMC Gastroenterol, 20, 35, 10.1186/s12876-020-1183-x · DOI
  52. Shi, 2023, Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis, J Clin Med, 12, 10.3390/jcm12031206 · DOI
  53. Romero-Mascarell, 2022, Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?, Diagnostics (Basel), 12, 10.3390/diagnostics12092226 · DOI
  54. Buisson, 2021, Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn’s Disease Regardless of Disease Location, Inflamm Bowel Dis, 27, 1008, 10.1093/ibd/izaa269 · DOI
  55. Simon, 2019, Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease?: a systematic review, Intest Res, 17, 160, 10.5217/ir.2018.00114 · DOI
  56. Zittan, 2018, Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn’s disease activity, JGH Open, 2, 201, 10.1002/jgh3.12068 · doi:10.1002/jgh3.12068
  57. 10.1111/jgh.14950 · DOI
  58. 10.1136/flgastro-2016-100686 · DOI
  59. Kennedy, 2019, Association Between Level of Fecal Calprotectin and Progression of Crohn’s Disease, Clin Gastroenterol Hepatol, 17, 2269, 10.1016/j.cgh.2019.02.017 · DOI
  60. 10.1055/s-2008-1077445 · DOI
  61. 10.1093/ECCO-JCC/JJY113 · DOI · Paper page
  62. 10.1055/s-0034-1391855 · DOI · Paper page
  63. Tamilarasan, 2022, The diagnostic yield of pan-enteric capsule endoscopy in inflammatory bowel disease: A systematic review and meta-analysis, J Gastroenterol Hepatol, 37, 2207, 10.1111/jgh.16007 · DOI
  64. Choi, 2017, Effectiveness of Capsule Endoscopy Compared with Other Diagnostic Modalities in Patients with Small Bowel Crohn’s Disease: A Meta-Analysis, Gut Liver, 11, 62, 10.5009/gnl16015 · DOI
  65. Kopylov, 2017, Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn’s disease: Systematic review and meta-analysis, Dig Liver Dis, 49, 854, 10.1016/j.dld.2017.04.013 · DOI
  66. Pasha, 2020, Capsule Retention in Crohn’s Disease: A Meta-analysis, Inflamm Bowel Dis, 26, 33, 10.1093/ibd/izz083 · DOI
  67. 10.1016/j.gie.2011.03.1239 · DOI · Paper page
  68. 10.1053/j.gastro.2014.04.008 · DOI
  69. Arulanandan, 2016, Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease, World J Gastroenterol, 22, 8999, 10.3748/wjg.v22.i40.8999 · DOI
  70. Zakeri, 2016, Diagnostic imaging and radiation exposure in inflammatory bowel disease, World J Gastroenterol, 22, 2165, 10.3748/wjg.v22.i7.2165 · DOI
  71. 10.1136/gut.2008.151415 · DOI · Paper page
  72. Bousorra, 2016, Radiation exposure in Crohn’s disease patients, Tunis Med, 94, 385
  73. 10.1053/j.gastro.2019.03.051 · DOI · Paper page
  74. Liu, 2017, A Diagnostic Accuracy Meta-analysis of CT and MRI for the Evaluation of Small Bowel Crohn Disease, Acad Radiol, 24, 1216, 10.1016/j.acra.2017.04.013 · DOI
  75. 10.1148/radiol.2471070611 · DOI · Paper page
  76. Greenup, 2016, Medical Imaging in Small Bowel Crohn’s Disease-Computer Tomography Enterography, Magnetic Resonance Enterography, and Ultrasound: “Which One Is the Best for What?”, Inflamm Bowel Dis, 22, 1246, 10.1097/MIB.0000000000000727 · DOI
  77. 10.1016/S2468-1253(18)30161-4 · DOI · Paper page
  78. Miles, 2019, Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden, Eur Radiol, 29, 1083, 10.1007/s00330-018-5661-2 · DOI
  79. 10.1111/j.1365-2036.2011.04710.x · DOI · Paper page
  80. 10.1016/j.crohns.2013.06.008 · DOI
  81. 10.1111/j.1365-2036.2007.03556.x · DOI · Paper page
  82. 10.1053/j.gastro.2020.03.039 · DOI · Paper page
  83. Castiglione, 2019, One-year clinical outcomes with biologics in Crohn’s disease: transmural healing compared with mucosal or no healing, Aliment Pharmacol Ther, 49, 1026, 10.1111/apt.15190 · DOI · Paper page
  84. Kumar, 2024, Magnetic Resonance Enterography and Intestinal Ultrasound for the Assessment and Monitoring of Crohn’s Disease, J Crohns Colitis, 18, 1450, 10.1093/ecco-jcc/jjae042 · DOI
  85. Ponsioen, 2017, Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial, Lancet Gastroenterol Hepatol, 2, 785, 10.1016/S2468-1253(17)30248-0 · DOI · Paper page
  86. Sands, 2018, The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease, J Crohns Colitis, 12, 883, 10.1093/ecco-jcc/jjy055 · DOI
  87. Herrera-deGuise, 2015, Predictive value of early restoration of quality of life in Crohn’s disease patients receiving antitumor necrosis factor agents, J Gastroenterol Hepatol, 30, 286, 10.1111/jgh.12803 · DOI
  88. 10.1055/s-2007-1021762 · DOI
  89. 10.1007/s10620-012-2072-0 · DOI
  90. Laube, 2018, Oral and upper gastrointestinal Crohn’s disease, J Gastroenterol Hepatol, 33, 355, 10.1111/jgh.13866 · doi:10.1111/jgh.13866
  91. Dąbkowski, 2019, Clinical significance of endoscopic findings in the upper gastrointestinal tract in Crohn’s disease, Scand J Gastroenterol, 54, 1075, 10.1080/00365521.2019.1656776 · doi:10.1080/00365521.2019.1656776
  92. 10.1097/MPG.0000000000000239 · DOI · Paper page
  93. Adamina, 2021, Ecco topical review Optimising reporting in surgery, Endoscopy, and Histopathology: collaboration between s-Ecco, Educom, H-Ecco, Journal of Crohn’s and Colitis, 15, 1089, 10.1093/ecco-jcc/jjab011 · DOI
  94. Feakins, 2022, ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease, J Crohns Colitis, 16, 343, 10.1093/ecco-jcc/jjab141 · DOI
  95. 10.1093/ECCO-JCC/JJAD142 · doi:10.1093/ecco-jcc/jjad142
  96. Magro, 2020, ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology, J Crohns Colitis, 14, 1503, 10.1093/ecco-jcc/jjaa110 · DOI · Paper page
  97. Sinopoulou V , Nigam GB , Gordon M , et al . Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2024. doi:10.1016/j.cgh.2024.11.008 · DOI
  98. 10.1097/00000478-199808000-00008 · DOI · Paper page
  99. 10.1111/j.1572-0241.1999.01533.x · doi:10.1111/j.1572-0241.1999.01533.x · Paper page
  100. 10.1136/gut.32.2.174 · DOI · Paper page
  101. 10.1136/gut.32.12.1514 · DOI · Paper page
  102. 10.1136/jclinpath-2013-201885 · DOI · Paper page
  103. 10.1136/jcp.2006.045336 · doi:10.1136/jcp.2006.045336
  104. 10.1046/j.1365-2559.2002.01416.x · doi:10.1046/j.1365-2559.2002.01416.x
  105. 10.1053/j.sempedsurg.2007.04.005 · DOI
  106. 10.1097/00000478-200211000-00006 · doi:10.1097/00000478-200211000-00006
  107. 10.1093/ecco-jcc/jjaa036 · DOI
  108. 10.1097/00000478-198911000-00008 · DOI
  109. Surawicz, 1984, Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease, Gastroenterology, 86, 104, 10.1016/0016-5085(84)90595-X · DOI · Paper page
  110. Rubio, 1994, “Nonspecific” erosions and ulcers of the colonic mucosa, Dig Dis Sci, 39, 821, 10.1007/BF02087429 · doi:10.1007/bf02087429
  111. 10.1053/j.gastro.2007.08.001 · DOI · Paper page
  112. 10.1136/gut.47.3.404 · DOI · Paper page
  113. 10.1136/bmj.1.4979.1315 · DOI · Paper page
  114. 10.1136/gut.29.5.669 · DOI · Paper page
  115. 10.1136/gutjnl-2015-310393 · DOI · Paper page
  116. 10.1093/ecco-jcc/jjaa010 · doi:10.1093/ecco-jcc/jjaa010
  117. Magro, 2020, Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels, J Crohns Colitis, 14, 169, 10.1093/ecco-jcc/jjz123 · doi:10.1093/ecco-jcc/jjz123
  118. 10.1111/j.1365-2036.2008.03835.x · DOI · Paper page
  119. 10.1097/MIB.0000000000000155 · DOI
  120. 10.1016/j.crohns.2014.08.011 · DOI · Paper page
  121. 10.1007/s00330-008-1290-5 · DOI
  122. Feakins RM . Transmural histology scores in stricturing Crohn’S disease: seeking to build precision on uncertain foundations. Oxford University Press UK, 2020:721–3. · DOI
  123. Neri, 2021, Histological scores in inflammatory bowel disease, J Dig Dis, 22, 9, 10.1111/1751-2980.12937 · DOI
  124. Almradi, 2021, An expert consensus to standardise the assessment of histological disease activity in Crohn’s disease clinical trials, Aliment Pharmacol Ther, 53, 784, 10.1111/apt.16248 · DOI · Paper page
  125. Salem, 2019, The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet?, Gastrointest Endosc Clin N Am, 29, 437, 10.1016/j.giec.2019.02.010 · DOI
  126. 10.1016/S0016-5085(98)70476-7 · DOI · Paper page
  127. Li, 2019, Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease, Gastroenterology, 157, 1019, 10.1053/j.gastro.2019.06.037 · DOI
  128. Novak, 2019, Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease, Aliment Pharmacol Ther, 49, 1401, 10.1111/apt.15250 · DOI
  129. Löwenberg, 2019, Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease, Gastroenterology, 157, 997, 10.1053/j.gastro.2019.05.067 · DOI
  130. Villanacci, 2017, Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study, Sci Rep, 7, 10.1038/s41598-017-07338-x · DOI
  131. Feagan, 2020, Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study, Lancet Gastroenterol Hepatol, 5, 819, 10.1016/S2468-1253(20)30188-6 · DOI
  132. 10.1038/ajg.2016.418 · DOI · Paper page
  133. 10.1136/gutjnl-2015-309598 · DOI · Paper page
  134. 10.1007/DCR.0b013e31819ad456 · DOI
  135. 10.1002/ibd.21268 · DOI
  136. 10.1159/000320415 · DOI
  137. Hyams, 2017, Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study, Lancet Gastroenterol Hepatol, 2, 855, 10.1016/S2468-1253(17)30252-2 · DOI
  138. Melson, 2010, Histopathology predictors of medically refractory ulcerative colitis, Dis Colon Rectum, 53, 1280, 10.1007/DCR.0b013e3181e751df · doi:10.1007/dcr.0b013e3181e751df
  139. Brennan, 2017, Clinical Implications of Histologic Abnormalities in Ileocolonic Biopsies of Patients With Crohn’s Disease in Remission, J Clin Gastroenterol, 51, 43, 10.1097/MCG.0000000000000507 · DOI
  140. Christensen, 2020, Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn’s Disease than Endoscopic Healing, Clin Gastroenterol Hepatol, 18, 2518, 10.1016/j.cgh.2019.11.056 · DOI
  141. Yoon, 2021, Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission, Inflamm Bowel Dis, 27, 1277, 10.1093/ibd/izaa301 · DOI
  142. 10.1053/j.gastro.2018.04.012 · DOI · Paper page
  143. Alves, 2022, The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis, JCR: Journal of Clinical Rheumatology, 28, e407
  144. Olivera, 2020, Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis, Gastroenterology, 158, 1554, 10.1053/j.gastro.2020.01.001 · DOI · Paper page
  145. 10.1002/art.11137 · DOI · Paper page
  146. Fehily, 2022, Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management, Aliment Pharmacol Ther, 56, 6, 10.1111/apt.16952 · DOI
  147. 10.1111/j.1572-0241.2008.02050.x · doi:10.1111/j.1572-0241.2008.02050.x
  148. Greenberg, 2008, Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis, J Rheumatol, 35, 770
  149. 10.1016/j.diagmicrobio.2010.12.020 · doi:10.1016/j.diagmicrobio.2010.12.020
  150. Ponce de Leon, 2008, Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population, J Rheumatol, 35, 776
  151. Park, 2022, Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis, JPM, 12, 507, 10.3390/jpm12030507 · DOI
  152. 10.1016/j.crohns.2011.09.011 · doi:10.1016/j.crohns.2011.09.011
  153. Kim, 2021, Low-dose steroids are associated with indeterminate QuantiFERON-TB Gold In-Tube assay results in immunocompetent children, Sci Rep, 11, 10.1038/s41598-021-86053-0 · DOI
  154. 10.1136/archdischild-2016-310870 · doi:10.1136/archdischild-2016-310870
  155. Dobler CC . Biologic agents and tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections 2017;623–35. doi:10.1128/9781555819866.ch37 · doi:10.1128/9781555819866.ch37
  156. de Francisco, 2018, Impact of Epstein‐Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease, Aliment Pharmacol Ther, 48, 723, 10.1111/apt.14933 · DOI
  157. 10.1016/S0140-6736(09)61302-7 · DOI · Paper page
  158. Zhang, 2022, Impact of Epstein–Barr virus infection in patients with inflammatory bowel disease, Front Immunol, 13, 10.3389/fimmu.2022.1001055 · DOI
  159. 10.1001/jama.2017.16071 · DOI · Paper page
  160. 10.1111/apt.12182 · DOI · Paper page
  161. Winthrop, 2023, Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib, Inflamm Bowel Dis, 29, 85, 10.1093/ibd/izac063 · doi:10.1093/ibd/izac063
  162. 10.1136/annrheumdis-2020-218510 · DOI · Paper page
  163. 10.1016/s0140-6736(21)00666-8 · DOI · Paper page
  164. Giri, 2023, Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis, Intest Res, 21, 392, 10.5217/ir.2022.00094 · DOI
  165. Magrì, 2021, Review article: safety of new biologic agents for inflammatory bowel disease in the liver, Eur J Gastroenterol Hepatol, 33, 623, 10.1097/MEG.0000000000002076 · DOI
  166. Chamberlain, 2014, Azathioprine can be safely used in HIV-infected individuals, AIDS, 28, 447, 10.1097/QAD.0000000000000121 · doi:10.1097/qad.0000000000000121
  167. Guillo, 2022, Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study, Clin Gastroenterol Hepatol, 20, 787, 10.1016/j.cgh.2020.12.023 · doi:10.1016/j.cgh.2020.12.023
  168. 10.1097/MIB.0000000000000338 · DOI
  169. 10.1016/j.suronc.2013.08.002 · DOI
  170. 10.1056/NEJMra1403718 · DOI · Paper page
  171. 10.1001/jama.2014.5613 · DOI · Paper page
  172. Scharl, 2019, Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study, Am J Gastroenterol, 114, 116, 10.1038/s41395-018-0360-9 · DOI
  173. 10.1053/j.gastro.2012.05.004 · DOI · Paper page
  174. 10.1111/bjd.15665 · DOI · Paper page
  175. Sands, 2020, Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis, Clin Gastroenterol Hepatol, 18, 123, 10.1016/j.cgh.2019.04.059 · DOI
  176. 10.1056/NEJMoa2109927 · DOI · Paper page
  177. 10.1111/apt.15514 · DOI · Paper page
  178. 10.1136/ard-2022-223715 · DOI
  179. 10.1093/ibd/izy243 · DOI
  180. 10.1136/gut.2010.224154 · DOI · Paper page
  181. 10.1016/j.crohns.2013.12.013 · DOI · Paper page
  182. Health. Do . Influenza: The Green Book, Chapter. 1920.
  183. deBruyn, 2016, Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial, Inflamm Bowel Dis, 22, 638, 10.1097/MIB.0000000000000615 · DOI
  184. Health Do . Chapter 18. In: Hepatitis B: The Green Book. 2017.
  185. Belle, 2015, Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases, Eur J Gastroenterol Hepatol, 27, 877, 10.1097/MEG.0000000000000370 · DOI
  186. 10.1111/jgh.13001 · DOI
  187. 10.1007/s10620-011-1980-8 · DOI
  188. 10.1111/j.1365-2036.2012.05110.x · DOI
  189. Alexander, 2021, SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement, The Lancet Gastroenterology & Hepatology, 6, 218, 10.1016/S2468-1253(21)00024-8 · DOI
  190. Do. Shingles: The Green Book, Chapter, n.d.:252024.
  191. 10.1136/gutjnl-2022-327570 · DOI
  192. Liu, 2023, Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study, EClinicalMedicine, 64, 10.1016/j.eclinm.2023.102249 · DOI
  193. Din, 2023, Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease, Aliment Pharmacol Ther, 57, 666, 10.1111/apt.17379 · DOI
  194. 10.1093/ecco-jcc/jjab052 · DOI · Paper page
  195. Department of Health . n.d. Contraindications and special considerations: the green book, Chapter 62013.
  196. Reich, 2016, Vaccinating patients with inflammatory bowel disease, Gastroenterol Hepatol (Bartlesville), 12, 540
  197. Chaudrey, 2015, Updates in vaccination: Recommendations for adult inflammatory bowel disease patients, WJG, 21, 3184, 10.3748/wjg.v21.i11.3184 · DOI
  198. Rahier, 2010, Vaccinations in patients with immune-mediated inflammatory diseases, Rheumatology (Sunnyvale), 49, 1815, 10.1093/rheumatology/keq183 · DOI · Paper page
  199. Do. Varicella: The Green Book, Chapter 34, 2015.
  200. 10.14309/ajg.0000000000000152 · DOI · Paper page

200 of 748 shown

Cited by

See all 169

Metadata

Authors
Moran, G. W., Gordon, M., Sinopoulou, V., Radford, S. J., Darie, A.-M., Vuyyuru, S. K., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., Chew, T., Colwill, M., Cooney, R., De Marco, G., Din, S., Din, S., Feakins, R., Gasparetto, M., Gordon, H., Hansen, R., Kok, K. B., Lamb, C. A., Limdi, J., Liu, E., Loughrey, M. B., McGonagle, D., Patel, K., Pavlidis, P., Selinger, C., Shale, M., Smith, P. J., Subramanian, S., Taylor, S. A., Tun, G. S. Z., Verma, A. M., & Wong, N. A. C. S.
Venue
Gut
Publisher
BMJ
Published
2025-06
Volume
74
Issue
Suppl 2
Pages
s1-s101
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4411623098
Cited by
169
References
20
FWCI
91.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. https://app.cochat.ai/papers/10.1136/gutjnl-2024-334395
The paper
Moran, G. W., Gordon, M., Sinopoulou, V., Radford, S. J., Darie, A.-M., Vuyyuru, S. K., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., Chew, T., Colwill, M., Cooney, R., De Marco, G., Din, S., Din, S., Feakins, R., Gasparetto, M., Gordon, H., . . . Wong, N. A. C. S. (2025). British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. https://doi.org/10.1136/gutjnl-2024-334395

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.